RenovoRx Inc RNXT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial
-
RenovoRx Announces Peer-Reviewed Publication Highlighting the TAMP™ Platform's Potential to Improve Chemotherapeutic Delivery for Locally Advanced Pancreatic Cancer
-
RenovoRx to Present at H.C. Wainwright 28th Annual Global Investment Conference, September 14th-16th
-
RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform’s Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer
-
RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
-
RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment
-
RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth
-
RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer
Trading Information
- Previous Close Price
- $1.14
- Day Range
- $1.15–1.19
- 52-Week Range
- $0.70–2.59
- Bid/Ask
- $0.88 / $1.39
- Shares Outstanding
- 45.13M
- Market Cap
- $54.16M
- Volume/Avg
- 164,335 / 781,688
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 22.89
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 17
- Website
- https://www.renovorx.com
Valuation
|
Metric
|
RNXT
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 5.73 |
Price/Sales | 22.89 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
RNXT
|
|---|---|
Quick Ratio | 5.29 |
Current Ratio | 5.74 |
Interest Coverage | — |
Quick Ratio
RNXT
Profitability
|
Metric
|
RNXT
|
|---|---|
Return on Assets (Normalized) | −100.19% |
Return on Equity (Normalized) | −131.78% |
Return on Invested Capital (Normalized) | −131.60% |
Return on Assets
RNXT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|vH&?sZ% | LOCK|?&LkW | $127B | |||
| Moderna Inc
MRNA
| LOCK|$nsC&& | LOCK|Q%D | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|>%S&x?y | LOCK|LP!! | $81B | |||
| argenx SE ADR
ARGX
| LOCK|!?N<^JH | LOCK|x&K | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|$Dy%@#B | LOCK|Fd | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|q&%&#rN | LOCK|L@&K | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|d#tRppN | LOCK|yqkZ> | $27B | |||
| Incyte Corp
INCY
| LOCK|MJmBtG> | LOCK|^> | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|DN>?$#& | LOCK|b@ | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|m^@czR | LOCK|SN | $14B |
United States